Kiniksa Pharmaceuticals International

KNSA | NASDAQ

Price Alert Chart Builder DCF Calculator

$78.13

+$0.89 (+1.15%)

At close: Sep 21, 2026, 4:00 PM ET

$78.70

+$0.57 (+0.73%)

Pre-market: Sep 22, 2026, 4:03 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $5.89B

Enterprise Value $5.44B

Beta 0.09

Average Volume 693.89K

Shares Outstanding (Diluted) 83.4M

Shares Change YoY 7%

Institutional Ownership 59.34%

Exchange NASDAQ

ISIN GB00BRXB0C07

Price Performance

Price Change 1M -1.5%

Price Change 3M 31.3%

Price Change 6M 70.4%

Price Change YTD 86.0%

Price Change 1Y 116.5%

Price Change 3Y 369.5%

Price Change 5Y 572.4%

1M CAGR (ann.) 0.9%

1Y CAGR (ann.) 118.0%

5Y CAGR (ann.) 44.2%

All-Time CAGR 18.0%

Valuation

PE Ratio 79.72

Forward PE 41.08

PEG Ratio 0.04

Forward PEG 1.53

PS Ratio 7.08

Forward PS 4.90

PB Ratio 9.10

P/FCF Ratio 32.52

P/Adj. FCF Ratio 40.41

P/OCF Ratio 32.69

EV/Sales 6.47

EV/EBIT 49.29

EV/EBITDA 48.50

EV/FCF 29.69

Earnings Yield 1.3%

FCF Yield 3.1%

Adj. FCF Yield 2.5%

Financial Health

Net Cash $525.93M

Total Debt $8.9M

Cash & Short-Term Investments $525.93M

Total Assets $896.11M

Current Ratio 3.90

Quick Ratio 3.49

Debt / Equity Ratio 0.01

Debt / EBITDA 0.08

Debt / FCF 0.05

OCF / Debt 20.82

Interest Coverage 0.00

Altman Z-Score 15.96

Piotroski F-Score 7

Margins & Profitability

Gross Profit Margin 54.5%

Operating Profit Margin 11.9%

EBITDA Margin 13.3%

Net Profit Margin 9.6%

FCF Margin 21.8%

Adj. FCF Margin 17.5%

SBC / Revenue 4.3%

SBC Impact (per share) -19.5%

Returns

Return on Assets 9.0%

Return on Equity 13.7%

Return on Invested Capital 9.7%

Return on Capital Employed 13.8%

Return on Tangible Assets 9.2%

Historical Growth (CAGR)

Revenue CAGR 3Y 44.1%

Revenue CAGR 5Y 155.6%

Revenue CAGR 10Y N/A

EPS CAGR 3Y -33.1%

EPS CAGR 5Y 39.2%

EPS CAGR 10Y N/A

FCF CAGR 3Y 62.8%

FCF CAGR 5Y 125.1%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 11

EPS Growth Next 3Y 41.2%

Revenue Growth Next 3Y 21.0%

Earnings Date Oct 26, 2026

EPS Estimate (next Q) $0.39

EPS Growth Est (next Q) 69.6%

Revenue Est (next Q) $259.65M

Revenue Growth Est (next Q) 43.6%

Fair Value Estimates

Graham Number $13.63

Graham Upside -82.5%

Lynch Fair Value $24.50

Lynch Upside -68.6%

Price Target $86.40

Price Target Upside 10.6%

Cash Flow

Operating Cash Flow $185.23M

Free Cash Flow $183.1M

Adj. Free Cash Flow $147.34M

FCF Per Share $2.36

OCF Per Share $2.39

OCF/S Ratio 22.0%

Income Statement

Revenue $840.85M

Gross Profit $546.22M

Operating Income $100.25M

EBITDA $112.09M

Net Income $80.66M

EPS (Diluted) $0.98

Revenue / Employee $2.3M

Profit / Employee $220.38K

Employees 366